Definium is in the final pivotal-data stretch for DT120 ODT, trying to turn a multi-indication psychedelic program into an NDA-ready franchise; Panorama was already scheduled for a late-third-quarter 2026 readout, so the timing was expected.
Panorama delivered the key efficacy result the program needed. The 100 µg dose beat placebo on the primary Week 12 HAM-A endpoint by 5.1 points, with a large-enough standardized effect size of 0.64 and significance well beyond the usual regulatory threshold. 〔0〕 This is above the trial’s success bar and adds a second positive Phase 3 GAD study after Voyage, while following the positive Emerge result in depression.
| Measure | DT120 ODT 100 µg | Placebo / comparison | Filing reference |
|---|---|---|---|
| Week 12 HAM-A LS mean change | −9.8 | −4.7 | (Panorama topline results) |
| Placebo-adjusted HAM-A difference | −5.1 points | — | (Panorama topline results) |
| Statistical significance | p<0.0001 | — | (Panorama topline results) |
| Standardized effect size | Cohen’s d=0.64 | — | (Panorama topline results) |
| Discontinuation rate | 10.4% | 10.3% placebo | (Safety results) |
| Overall TEAE rate | 94.8% | 62.9% placebo | (Safety results) |
| Participants meeting EoSC criteria by hour 8 | 94% | — | (Treatment-session monitoring) |
The result meaningfully strengthens the NDA narrative, but does not eliminate execution risk. Management now has three positive Phase 3 readouts for DT120 ODT, and the company says it is advancing toward an NDA submission. 〔1〕 The next regulatory step is the planned pre-NDA meeting in the fourth quarter of 2026, with an anticipated NDA filing in the first half of 2027. Those dates are company targets, not approvals.
The main unresolved issue is operational rather than clinical. Patients were monitored for at least eight hours after dosing, and 94% of Panorama participants met the company’s end-of-session criteria by hour eight; across more than 1,000 Phase 3 treatment sessions, the figure was 97%. 〔2〕 That supports a potentially manageable treatment-center model, but it also means DT120 is unlikely to launch like a conventional daily prescription, with site capacity, staffing, controlled-substance rules, reimbursement, and patient throughput still to be resolved.
Safety was acceptable for this development stage, but the treatment experience remains conspicuous. No new safety signals or drug-related serious adverse events were reported, and discontinuation was similar to placebo. However, the overall adverse-event rate was much higher than placebo, with illusion, nausea, and headache among the most common dosing-day events. 〔3〕
Bottom line: Panorama converts DT120’s GAD story from a promising single-study case into repeat Phase 3 evidence and materially advances the NDA path. The clinical hurdle is increasingly de-risked; the remaining challenge is proving that an eight-hour, psychedelic-assisted treatment model can be deployed at scale.
Read the original 8-K on SEC EDGAR ↗